Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced/ Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid Tumors

 Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced/ Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid Tumors

Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced / Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid Tumors

Shots:

  • Oncorus has initiated a P-I study assessing ONCR-177 as monothx. and in combination with Merck’s Keytruda in patients with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
  • The P-I study enrolls ~21 cancer patients while P-II study enrolls patients to histology- specific expansion cohorts. The P-I study will evaluate the safety and tolerability and determine the recommended P-II dose and as preliminary anti-tumor activity of ONCR-177 as monothx. & combination therapy
  • The planned expansion cohorts will include patients with BC, SCCHN, and melanoma. ONCR-177 is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy and is armed with oHSV, IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4 designed to stimulate multiple arms of the immune system

Click here to read full press release/ article | Ref: Oncorus | Image: Pitt Innovation System

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post